UY28438A1 - Composicion de un antagonista de vegf y de un agente antiproliferativo - Google Patents

Composicion de un antagonista de vegf y de un agente antiproliferativo

Info

Publication number
UY28438A1
UY28438A1 UY28438A UY28438A UY28438A1 UY 28438 A1 UY28438 A1 UY 28438A1 UY 28438 A UY28438 A UY 28438A UY 28438 A UY28438 A UY 28438A UY 28438 A1 UY28438 A1 UY 28438A1
Authority
UY
Uruguay
Prior art keywords
antiproliferative agent
composition
vegf antagonist
vegf
taxol
Prior art date
Application number
UY28438A
Other languages
English (en)
Inventor
Jocelyn Holasch
Robert Jaffe
George D Yancopoulos
Limin Hu
Original Assignee
Univ California
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Regeneron Pharma filed Critical Univ California
Publication of UY28438A1 publication Critical patent/UY28438A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para tratar al cáncer y/o reducir o inhibir el crecimiento tumoral en un sujeto con dicha necesidad, que comprenda el administrar un composición farmacéutica comprendiendo un antagonista de factor de crecimiento de células del endotelio vascular (VEGF), tal como una trampa de VEGF, y un agente antiproliferativo, tal como taxol, y un portador farmacéuticamente aceptable.
UY28438A 2003-07-25 2004-07-26 Composicion de un antagonista de vegf y de un agente antiproliferativo UY28438A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49000203P 2003-07-25 2003-07-25
US49397103P 2003-08-08 2003-08-08

Publications (1)

Publication Number Publication Date
UY28438A1 true UY28438A1 (es) 2004-11-08

Family

ID=34118812

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28438A UY28438A1 (es) 2003-07-25 2004-07-26 Composicion de un antagonista de vegf y de un agente antiproliferativo

Country Status (17)

Country Link
US (1) US7354579B2 (es)
EP (1) EP1648428A2 (es)
JP (1) JP5355856B2 (es)
KR (1) KR101175990B1 (es)
AR (1) AR046510A1 (es)
AU (1) AU2004261165C1 (es)
BR (1) BRPI0412798A (es)
CA (1) CA2529742C (es)
IL (1) IL172406A (es)
MX (1) MXPA05013642A (es)
MY (1) MY149169A (es)
NO (1) NO20060924L (es)
NZ (1) NZ544570A (es)
RU (1) RU2353353C2 (es)
TW (1) TWI351953B (es)
UY (1) UY28438A1 (es)
WO (1) WO2005011734A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7354581B2 (en) * 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
PT1853250E (pt) * 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
KR20080077238A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20100047234A1 (en) * 2007-03-14 2010-02-25 Markovic Svetomir N Treating skin cancer
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
LT5610B (lt) 2007-12-17 2009-11-25 Uab Baltec Cnc Technologies, , Kompleksinė sveikatinimo ir sporto įrangos sistema ir jos įgyvendinimo būdas
KR20180128078A (ko) * 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2017197199A1 (en) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
US11059885B2 (en) 2016-05-13 2021-07-13 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
JP2020510673A (ja) 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
MA52570A (fr) 2018-05-10 2021-03-17 Regeneron Pharma Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
KR20240008821A (ko) 2021-05-17 2024-01-19 리제너론 파아마슈티컬스, 인크. 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
JP2023135645A (ja) 2022-03-15 2023-09-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン
WO2023177691A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors

Also Published As

Publication number Publication date
KR20060028654A (ko) 2006-03-30
RU2006105496A (ru) 2006-06-10
WO2005011734A3 (en) 2005-04-14
US7354579B2 (en) 2008-04-08
IL172406A0 (en) 2006-04-10
NZ544570A (en) 2008-08-29
WO2005011734A2 (en) 2005-02-10
IL172406A (en) 2016-04-21
KR101175990B1 (ko) 2012-08-23
TW200524589A (en) 2005-08-01
CA2529742C (en) 2012-09-18
MY149169A (en) 2013-07-31
AR046510A1 (es) 2005-12-14
JP2007500131A (ja) 2007-01-11
MXPA05013642A (es) 2006-03-10
EP1648428A2 (en) 2006-04-26
AU2004261165C1 (en) 2009-12-17
US20050032699A1 (en) 2005-02-10
BRPI0412798A (pt) 2006-09-26
JP5355856B2 (ja) 2013-11-27
AU2004261165A1 (en) 2005-02-10
TWI351953B (en) 2011-11-11
NO20060924L (no) 2006-04-25
RU2353353C2 (ru) 2009-04-27
AU2004261165B2 (en) 2009-07-16
CA2529742A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
UY28438A1 (es) Composicion de un antagonista de vegf y de un agente antiproliferativo
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
AR058126A1 (es) Antagonistas y conjugados del peptido cgrp
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
AR090143A2 (es) Composicion farmaceutica para inhibir el crecimiento de celulas anormales
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CL2009000133A1 (es) Compuestos derivados de ftalazinona, inhibidores de la actividad parp; composicion farmaceutica; uso en el tratamiento de enfermedades vasculares, shock septico, lesion isquemica, neurotoxicidad, shock hemorragico, como auxiliar en la terapia del cancer de mama, de ovario, de pancreas, entre otras.
CR9518A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores
CL2009000816A1 (es) Metodos para modificar una estructura especifica asociada a una actividad biologica; ysu uso en el tratamiento de enfermedades y sintomas como son autoinmune, oculares, snc, cancer, entre otras.
UY31017A1 (es) Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
AR044039A1 (es) Combinaciones antineoplasicas
AR112103A1 (es) Compuestos para el tratamiento de tnbc
AR074603A1 (es) Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
AR071309A1 (es) Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten
AR067420A1 (es) Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan
RU2008148597A (ru) Фармацевтические комбинации
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20151204